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Abstract: In recent years, the clinical use of high-resolution com-
puted tomography has greatly advanced the diagnosis of small
lesions of the peripheral lung. Such small lesions are often associ-
ated with ground-glass opacity in computed tomography findings.
The noninvasive bronchioloalveolar carcinoma component with a
replacement growth pattern of alveolar lining cells manifests as
ground-glass opacity. Bronchioloalveolar carcinoma is classified as
a subset of lung adenocarcinoma, but has a distinct clinical presen-
tation, tumor biology, and favorable prognosis. Most small periph-
eral lung lesions including bronchioloalveolar carcinoma putatively
originate from the peripheral airway epithelium, in which the epi-
dermal growth factor receptor gene is frequently mutated. As with
other subsets of non-small cell lung cancer, surgical resection is a
potentially curative treatment. For the ground-glass opacity type of
tiny lesions, particularly those less than 1 cm in their greatest
dimension, the question has been raised whether lobectomy is really
needed. Although several authors in Japan suggest the suitability of
limited resection including segmentectomy and wedge resection
without any nodal dissections for these small lung adenocarcinomas,
this procedure should be validated in future clinical trials.
Key Words: Atypical adenomatous hyperplasia, Bronchioloalveo-
lar carcinoma, Ground-glass opacity.
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The use of recently developed methods of radiographicinvestigation, particularly low-dose helical computed to-
mography (CT) for lung cancer, has increased the detection
of small lesions in the peripheral lung.1,2 Ground-glass opac-
ity (GGO) is a finding on CT images of the lung that is
usually nonspecific and may be found in many kinds of
pulmonary disease, such as inflammation, bleeding, pulmo-
nary lymphoproliferative disorder, atypical adenomatous hy-
perplasia (AAH), bronchioloalveolar carcinoma (BAC), and
well-differentiated adenocarcinoma.3,4 When focal GGO per-
sists after observation over several months, early adenocar-
cinoma or BAC is highly suspected.5 In the revised World
Health Organization (WHO) histologic classification, BAC is
classified as a noninvasive carcinoma with no evidence of
stromal, vascular, or pleural invasion.
Although the therapeutic results for lung cancer are
unsatisfactory, good results have been obtained in patients
with stage I cancer. Recently, it was reported that annual
spiral CT screening can detect lung cancer that is curable in
a large collaborative study that screened more than 30,000
asymptomatic persons.6 The screening resulted in a diagnosis
of 412 clinical stage I lung cancer, and the estimated 10-year
survival rate was 88%. Although lobectomy with mediastinal
lymph node dissection is considered to be appropriate surgi-
cal procedure for T1 N0 M0 non-small cell lung cancer
(NSCLC), it is not certain whether lobectomy is really needed
for the GGO type of such small lesions. Furthermore, it is
also not known whether pulmonary resection is really neces-
sary for such small lesions.
To manage and treat this growing entity of small lung
adenocarcinoma, it is necessary to understand the features of
these tumors. This article reviews the current information on
the histopathology, tumor biology, natural history, radio-
graphic findings, and surgical treatment of early-stage periph-
eral lung adenocarcinomas.
HISTOPATHOLOGY
Most small lesions of the peripheral lung that are not
detectable on chest radiographs are diagnosed pathologically
as focal BAC or AAH, a precancerous lesion.5,7 In contrast,
small lung lesions detected on chest radiographs include
squamous cell carcinomas and poorly differentiated adeno-
carcinomas, which form solid nodules.
In the study of stage I adenocarcinomas less than 2 cm
in diameter by Noguchi et al.,8 patients with pure BAC
(Noguchi type A) and BAC with foci of structural collapse of
alveoli (Noguchi type B) had a better 5-year survival rate
(100%) than patients with foci of active fibroblastic pro-
liferation (Noguchi type C, 75% survival rate) or pure
adenocarcinoma (Noguchi types D–F, 52% survival rate).
These findings greatly influenced the 1999 WHO/Interna-
tional Association for the Study of Lung Cancer Classifica-
tion Panel, which proposed a new, stricter definition of BAC
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that required it to show pure lepidic growth without invasion
of stroma, pleura, or blood vessels.7
Liebow9 first reported BAC in 1960, describing the
tumor as a well-differentiated adenocarcinoma with neoplas-
tic cells spreading along alveoli, but with little stromal reac-
tion, no invasion, and preservation of alveolar structure.
According to the WHO criteria, BAC is a carcinoma in situ,
and a tumor cannot be classified as a BAC if it is associated
with lymphatic or systemic metastases. BAC is classified
further into nonmucinous (60%–80%) and mucinous
(20%–40%) types. Nonmucinous BAC is associated with
proliferation of Clara cells, nonciliated bronchial epithe-
lium, or type II pneumocytes. Histologic findings in mu-
cinous BAC include goblet cells or mucin-producing co-
lumnar tumor cells. Tumors with BAC features and areas of
invasion are classified as adenocarcinomas of mixed sub-
types, and there is evidence that the presence of any BAC
features predicts improved survival compared with pure
adenocarcinoma.7,8,10–13 However, it is still controversial
whether a greater proportion of BAC features is a better
predictor of survival than is a lower proportion of BAC
features
Diagnosing BAC requires histologic examination for
the presence or absence of invasion. Cytology is inadequate
for the diagnosis of BAC. The sensitivity and specificity of
cytology for the diagnosis have not been reported. For similar
reasons, frozen section diagnosis of BAC, which involves
examining a small portion of the tumor, is probably unreli-
able. Therefore, diagnosis usually depends on the radio-
graphic findings, which correlate closely with the pathologic
diagnosis in the decision of treatment options including
surgery.
Another major change in the WHO classification in
1999 was the addition of AAH as a precursor lesion for lung
adenocarcinoma. This was preserved in the 2004 WHO
classification. AAH is a solitary alveolar lesion, usually less
than 5 mm in diameter, accompanied by proliferation of type
II pneumocyte-like or Clara cell-like cells with varied cellular
atypia.7 Some lesions may exhibit foci of increased atypia
that may warrant a diagnosis of BAC. Moreover, AAH
lesions are seen occasionally in the periphery of indisputable
adenocarcinoma. Miller et al.14 suggested that AAH might be
analogous to adenomatous lesion of the colon, and subse-
quent studies have supported this hypothesis.15,16
TUMOR BIOLOGY
Compared with other subtypes of NSCLC, little is
known about the biology of AAH and BAC. According to the
adenoma–carcinoma sequence, originally proposed in colon
cancer, at least one type of lung adenocarcinoma is supposed
to develop from AAH through BAC to adenocarcinoma. This
hypothesis is based on the findings that foci of AAH and
BAC are found frequently in association with adenocarci-
noma and that genetic mutations and chromosomal abnormal-
ities accumulate sequentially in samples of AAH, BAC,
mixed BAC, and adenocarcinomas.17,18
Although p53 is altered frequently in lung adenocarci-
noma, this gene is mutated infrequently in BAC. Only less
than 14% of BAC tumors harbor p53 mutations, compared
with 53% of non-BAC adenocarcinomas.12,19,20 Nakanishi et
al.21 found that survivin was expressed in all 40 BAC tumors
examined, compared with just 9% of low-grade AAHs. This
implies a resistance to apoptotic signaling in BAC compared
with AAH. Overexpression of HER2 is common in BAC and
non-BAC adenocarcinomas.
Epidermal growth factor receptor (EGFR) is frequently
overexpressed and aberrantly activated in NSCLC. Origi-
nally, EGFRmutations were predominantly found in females,
nonsmokers, adenocarcinomas, and Asian patients.22,23 In
terms of morphologic and pathologic features, we found that
the EGFR gene mutations predominantly occur in adenocar-
cinomas originated from the peripheral airway epitheli-
um.24,25 Interestingly, some AAH occasionally harbor EGFR
mutations, suggesting that EGFR mutations occur relatively
early in pathogenesis.24
Activating K-ras mutations were the most extensively
investigated genetic alterations in AAH, and the frequency of
K-ras mutations was 15% to 50%.15 A series of analysis in
AAH, BAC, and adenocarcinoma detected K-rasmutations in
27% of AAH, 17% of BAC, and 10% of invasive adenocar-
cinomas,26 suggesting that this is an initiating event in lung
tumorigenesis. In agreement with other reports, EGFR muta-
tions never occur in tumors with K-ras mutations.
At present, although genetic alterations of p53, EGFR,
and K-ras seem to be associated with the progression from
AAH through BAC to adenocarcinoma in the lung, they may
not be indicators of treatment strategy for lung cancer. It
would be a desirable goal to determine the molecular lesions
that could serve as an indication for limited pulmonary
resection.
Patients with NSCLC sometimes show a dramatic re-
sponse to EGFR tyrosine kinase inhibitors such as gefitinib
and erlotinib. Investigators have found that mutations in the
tyrosine kinase domain of the EGFR gene correlate with the
response to EGFR tyrosine kinase inhibitors.22,23 Amino acid
substitutions or deletions in exons 18, 19, and 21 were found
in 80% of responders to gefitinib compared with 12% of
nonresponders.27 The observation that EGFR mutations seem
to occur relatively early in pathogenesis is closely associated
with reports that gefitinib sensitivity is high in patients with
adenocarcinomas with BAC features.28 In clinical trials eval-
uating the use of gefitinib in advanced-stage chemotherapy-
refractory NSCLC, objective clinical responses were seen in
38% of patients with BAC compared with 8% of patients with
non-BAC adenocarcinomas.28
NATURAL HISTORY OF SMALL LUNG
LESIONS WITH GGO
An important issue is the management of small cancers,
especially those showing pure GGO as the dormant lesion.
Among patients diagnosed as Noguchi type A, which has a
100% 5-year survival rate, those who did not need resection
might be included in the subgroup. Although it has been
suggested that the adenoma–carcinoma sequence also applies
to tumorigenesis in adenocarcinoma of the lung, no persua-
sive data have been presented on the percentage of the
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nonsolid type of GGO lesions that are indolent over a long
clinical course or the percentage of GGO lesions that progress
to become solid lesions. The time frame for small GGO
lesions to progress to solid tumors is also unclear. To avoid
an overdiagnosis bias, it is important to elucidate the natural
history of the small lung nodules showing GGO features.
Serial CT studies with follow-up have demonstrated
progression of lung adenocarcinomas with GGO components.
Lung adenocarcinomas initially presenting as GGO subse-
quently increased in size in 75% of patients and developed
solid components within the nodule in 17% of patients. The
solid portions increased in 23% of patients, and spiculation
appeared in 6% of patients.29 Other authors reported three
types of progression of BAC: (1) increasing size in BAC, (2)
decreasing size with the appearance of a solid component in
one BAC and one adenocarcinoma with mixed subtype, and
(3) stable size and increasing density in BAC. All but one of
the follow-up cases of lung cancers were noninvasive,
whereas the remaining tumor showing GGO with a solid
component was minimally invasive.30 In the review of the
natural history of pure GGO through long-term observation in
19 patients, the size of pure GGO did not change in eight
patients, increased slightly (up to 5 mm) in six patients, and
increased by more than 5 mm in five patients during a
follow-up of 2 years or more. Among the 10 patients who
underwent limited resection, five had adenocarcinoma, three
had pulmonary lymphoproliferative disorder, one had AAH,
and one had focal fibrosis. The authors suggested that some
pure GGOs would never progress to clinical disease.4 In our
institution, we reviewed 10 patients with GGO on CT who
had no intervention for more than 2 years (median follow-up,
32 months; range, 24–72). The size of lung lesions at the time
of discovery was 8 to 21 mm in largest diameter. During
follow-up, the size of the lesions did not change or increased
slightly (up to 5 mm) in all but two of the 10 patients (Figure
1). In one of the 10 patients, the lesion became larger,
increasing to 23 mm in diameter during follow-up of 33
months (Figure 2). In another patient, the lesion became
slightly larger and multiple new GGOs appeared during
follow-up of 45 months (Figure 3). Six of the 10 patients had
a history of lung adenocarcinoma.
When the size of GGO remains stable or increases only
slightly over a long period, the clinician may consider a
variety of histologic entities. Previous reports have often
suggested that the management of GGO lesions should differ
from the management of small, peripheral, noncalcified sol-
itary nodules showing soft-tissue density. These have also
recommended wide wedge resection or segmentectomy as a
safe and minimally invasive procedure in the treatment of
these small GGO lesions.
RADIOGRAPHIC EVALUATION
OF INVASIVENESS
Radiographic findings suggest that small peripheral
lung adenocarcinoma is often associated with GGOs.31–33 The
strong correlation between CT and pathologic features was
reported in many radiographic studies on solitary, peripheral,
small lung adenocarcinomas. Concerning the size of the
lesion, Asamura et al.34 studied 48 lung carcinomas measur-
FIGURE 1. Computed tomography (CT)
from representative case with long-term fol-
low-up of small lung lesions. CT images
from a 53-year-old woman. (A) A thin-sec-
tion CT scan shows a 10-mm diameter
small pure ground-glass opacity (GGO) in
the right upper lobe with indistinct bound-
ary and hazy attenuation. (B) After a 24-
month follow-up, the size of GGO did not
change. In the 10 patients with GGO whom
we observed for more than 2 years, the size
of the lesion did not change or increased
slightly (up to 5 mm) in eight patients.
FIGURE 2. Computed tomography images
from a 60-year-old man. (A) A thin-section
CT scan shows ground-glass opacity (GGO)
with higher attenuation in the central part
of the tumor in the left upper lobe, which
measured 15 mm in diameter. (B) During
follow-up of 33 months, the lesion became
larger, increasing to 23 mm in diameter.
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ing 1 cm or less and found three high-resolution CT patterns:
nonsolid GGO type (n  19), part-solid GGO type (n  9),
and solid type (n  20). They found no recurrences or BAC
histologic type for all 28 GGO (nonsolid and part-solid)
lesions. However, not all pure GGO lesions are pure BAC
histologically, and some can have a component of invasive
adenocarcinoma.34 In the comprehensive analyses of hilar
and mediastinal lymph node dissected systematically, nodal
micrometastasis was found in 20% of the patients with
adenocarcinoma of 1.1 to 2.0 cm in diameter and even in four
of 11 patients with adenocarcinoma of 1.0 cm or less.35 The
frequency of lymph node metastasis in small lung cancer 1
cm or less in diameter is shown in Table 1.34–38 Therefore,
tumor size alone cannot be a positive indicator for noninva-
sive nature of the small lung adenocarcinomas.
Increased lymph node metastasis and pleural and vas-
cular invasion were suggested to be associated with greater
scarring and fibrotic focus in the tumor. A summary of
detailed correlations between CT findings and pathologic
features is shown in Table 2.32,39–41 In addition, Yang et al.42
found that 94% of pure BAC without alveolar wall collapse
demonstrate pure GGO by CT, whereas 71% of BAC with
some alveolar wall collapse appear as heterogeneous, low-
attenuation nodules. They also found that 50% of mixed
subtype adenocarcinomas with a BAC component are homo-
geneous nodules with a soft-tissue density and that 29%
appear as nodules with ground-glass attenuation in the pe-
riphery and a high-density central zone. Using univariate
analysis, the lesion size of 15 mm, GGO areas greater than
57%, and BAC histology correlate with a favorable progno-
sis, although multivariate analysis showed that the percentage
of GGO areas was the only independent prognostic factor.40
These authors also demonstrated that air bronchograms and
histologic grade were of prognostic importance in multivar-
iate analysis of 52 patients with mixed subtype lung adeno-
carcinomas with a BAC component. In addition, Okada et
al.43 showed a correlation between tumor shadow disappear-
ance rate, which is defined as the ratio of the tumor area of the
mediastinal window to that of the lung window on high-
resolution CT, and the percentage of BAC histology in
resected specimens in tumors less than 3 cm. In this way,
classification by the percentage of GGO areas in addition to
the size of tumor seems to be more suitable in the selection of
patients for limited surgery as described later.
Conversely, Nomori et al.44,45 have used other unique
approaches to quantify or describe small lesions using CT and
other new technology such as positron emission tomography
(PET). They made histograms of pixel CT numbers for AAH,
nonmucinous BAC, and adenocarcinoma and quantified the
peak and mean CT numbers on the histograms. The peak CT
number can help in the radiographic differentiation between
AAH and BAC. In addition, clinical T1 N0 M0 adenocarci-
nomas with a peak at a low CT number on the histogram
seldom have lymph node metastasis or tumor involvement of
vessels or pleura. PET is considered a sensitive imaging
modality to differentiate benign from malignant lung lesions.
PET with 11C-acetate (AC) has been reported recently to
detect slow-growing tumors such as well-differentiated hep-
atocellular carcinomas and prostate cancers. In the study of
54 pulmonary nodules 1 to 3 cm in size that appeared as GGO
on CT by AC-PET, they detected approximately one third of
the well-differentiated adenocarcinomas of the lung not iden-
tified by fluorodeoxyglucose-PET.46
SURGICAL TREATMENT
According to the only prospective, randomized trial by
the Lung Cancer Study Group in 1995, the appropriate
surgical procedure for T1 N0 M0 NSCLC is lobectomy with
mediastinal lymph node dissection.47 This study demon-
strated that a lesser resection such as wedge or segmentec-
tomy has three times more local recurrence than a lobectomy.
However, it may not be appropriate to simply apply these
results to the treatment of small-sized lung adenocarcinomas
showing GGO on CT because such tumors were not recog-
FIGURE 3. Computed tomography (CT)
images from a 60-year-old man. (A) A CT
scan shows a small pure ground-glass opac-
ity (GGO) in the left lower lobe (arrow). (B)
During follow-up of 45 months, the lesion
became slightly larger and multiple new
GGOs appeared (arrow).
TABLE 1. Frequency of Lymph Node Involvement in











Ohta et al.35 2001 11 3 1 4 (36)
Miller et al.36 2002 100 5 2 7 (7)
Asamura et al.34 2003 48 2 1 3 (6)
Ikeda et al.37 2004 47 0 1 1 (2)
Okada et al.38 2005 50 0 1 1 (2)
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nized at the time of this study. For the GGO type of tiny
lesions, particularly those less than 1 cm in their greatest
dimension, the question has been raised whether lobec-
tomy is really needed. Essentially, radical resection by
lobectomy and hilar–mediastinal lymph node dissection
should be indicated only for tumors with present or pos-
sible risk of invasion.
There are six studies that deal with limited resection
for small-sized lung cancers with a median follow-up of 29
to 50 months; all patients were alive and without recur-
rence (Table 3).48–53 In addition, the comparisons of lim-
ited resection with conventional lobectomy are shown in
Table 4.36,38,54,55 Some of these results show satisfactory
5-year survival rates. Concerning the surgical approach for
small lung cancers, wedge resection or segmentectomy by
video-assisted thoracic surgery (VATS) without lymph node
dissection is one type of minimally invasive surgery. Show-
ing that some types of lung cancer can be resected by VATS
without an increase in local recurrence would increase the use
of this method as future standard treatment for peripheral
small lung cancers.
However, even if limited resection is possible, there are
problems with drawing conclusions from the studies described
above because, in most, follow-up is short in a clinical situation
where patients are at risk of recurrence for up to 10 years. Also,
patient numbers are small, patients are not randomized, and
tumor invasion cannot always be determined until permanent
sections are viewed. In addition, some have expressed different
opinions about the limited resection.36,56 Barlesi et al.56 indicated
that completely resected BAC is associated with a 5-year sur-
vival rate of 48% to 69%. Of patients who experience recur-
rence, 76% to 95% recur locally initially, a rate higher than that
of other subtypes of NSCLC. Survival after surgical resection
is associated with the early-stage, nonmucinous subtype and
the absence of vascular or lymphatic invasion. Most BAC
tumors have an invasive component, and it is not possible to
differentiate accurately between pure and mixed BAC by
needle biopsy or frozen-section pathology results.36 It is also
unclear whether a higher proportion of BAC histology pre-
dicts improved survival.8,12,13,57
Accordingly, there is still controversy about the limited
resection of peripheral small lung cancers, and clinical evi-
TABLE 2. Correlation between the Ratio of Ground-Glass Opacity and Pathological Diagnosis
Author Year GGO Histologic Classification
Pure BAC Mixed Subtype Adenocarcinoma
Aoki et al.39 2001 10% 1 42 30
10%–50% 8 21 1
50% 18 6 0
BAC  50% BAC 50%
Kodama et al.32 2001 50% 36 2
50% 16 50
Pure BAC Mixed Subtype Adenocarcinoma
Matsuguma et al.41 2002 0% 1 1 37
1%–25% 1 2 19
26%–50% 1 2 6
51%–75% 6 3 2
76%–100% 12 2 1
Noguchi A, B Noguchi C
Takashima et al.40 2002 10% 0 7
10%–50% 4 14
50% 31 6
BAC, bronchioloalveolar carcinoma; GGO, ground-glass opacity.






Yamato et al.50 2001 BAC, 20 mm 36 34 wedge, 2 seg 30 None
Watanabe et al.49 2002 Pure GGO, 5–12 mm 17 14 wedge, 3 seg 32 None
Yamada et al.51 2004 Pure GGO, 20 mm 25 22 wedge, 3 seg 29 None
Nakamura et al.48 2004 Pure GGO, 6–12 mm 27 Wedge or seg 32 None
Yoshida et al.47 2005 GGO, 6–21 mm 26 23 wedge, 3 seg 50 None
Nakata et al.52 2005 GGO 90%, 6–18 mm 16 15 wedge, 1 seg 25 None
BAC, bronchioloalveolar carcinoma; GGO, ground-glass opacity; seg, segmentectomy; seg, segmentectomy; wedge, wide wedge
resection.
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dence is needed to demonstrate the effectiveness of limited
resection for such tumors. In the recent report from the Japan
Lung Cancer Surgical Study Group, a radiographic noninva-
sive cancer was defined as a tumor having consolidation of
less than half of the maximum tumor dimension. A patho-
logic noninvasive cancer that is a future candidate for limited
surgery was defined as a tumor with no lymph node metas-
tasis or lymphatic or vascular invasion. The study group
evaluated centrally reviewed 545 tumors resected by lobec-
tomy. The specificity for the diagnosis of pathologic nonin-
vasive cancer was 96.4%, meaning that 3.6% of pathologic
invasive cancer showed radiographic noninvasive cancer.58
Although radiographic findings on CT could not definitely
rule out the invasive cancer, considering the extremely low
chance of invasive features in the pure GGO type of small
lung cancers, limited resection might be justified. A prospec-
tive phase II study of limited surgical resection for peripheral
lung cancer 2.0 cm or less in size is now planned based on the
results of exploratory analysis of the study.58
Furthermore, classifying patients based on molecular
biology including specific gene alterations such as p53 mu-
tations and aberrant expressions of Ki-67, K-ras, Laminin-5,
-catenin, and E-cadherin appears to be attractive in select-
ing patients with small-sized lung cancers suitable for limited
resection.59
CONCLUSION
With the growing use of high-resolution CT, the inci-
dence of small lung lesions, especially adenocarcinoma in-
cluding BAC, may increase. The new entity of this lung
lesion is distinct in terms of its pathology, radiographic
findings, natural history, and treatment.
A great deal remains to be learned about tumor biology
and surgical treatment to define a minimally invasive cate-
gory. It is particularly important that careful radiology-pa-
thology correlation studies are conducted in many countries
to help validate or modify the existing criteria. The features,
including CT images, of small noninvasive lung adenocarci-
nomas suitable for limited resection without lymph node
dissection should be clarified by clinical multicenter studies.
This will make it possible to determine the optimal CT
findings for limited resection.
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